markets · marketwatch.com

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
Image via marketwatch.com
What happened

On June 2, 2024, Moderna Inc. released the first Phase 3 results for its mRNA‑4157 cancer vaccine combined with Merck's Keytruda in a 1,200‑patient melanoma trial. The data showed a 12‑month disease‑free survival (DFS) of 71% versus 66% for Keytruda alone, but no statistically significant improvement in overall survival (OS) at 24 months, and the FDA advisory panel raised concerns about the vaccine's ability to prevent recurrence long‑term.

Why it matters

The modest DFS gain suggests the vaccine may add value only in a narrow therapeutic window, limiting its commercial upside in a market dominated by checkpoint inhibitors. Moreover, the lack of OS benefit raises questions for payers about reimbursement and could dampen investor enthusiasm for Moderna's oncology pipeline.

Your next move — for a otherIf you work in pharma operations, start mapping the supply‑chain implications of a dual‑product (vaccine + checkpoint inhibitor) launch, focusing on cold‑chain logistics for mRNA. For consultants, develop a briefing note on the risk of investing in late‑stage oncology assets that lack clear OS advantage, using Moderna's data as a concrete example.
Read full article ↗